Expert Interview
Discussing the Potential of Allergan's (AGN) Recently Acquired XAF5 in Treating Under-Eye Bags Ahead of Phase IIb/III Completion in Late 2016
Ticker(s): AGN, Topokine TherapeuticsAn expert with significant experience treating patients with steatoblepharon (under eye bags), who is familiar with the data behind XAF5. He or she will be familiar with other treatment options, and the regulatory process for this space.
Can you describe your experience treating patients with under eye bags? What current drugs are used in treatment? What other ways can under eye bags be treated?
Added By: pjloriaThere are an estimated 40 million people in the U.S with under eye bags. About what percentage of that population do you think is actively seeking treatment for their condition?
Added By: pjloriaCan you discuss the data from the Phase II XOPH5-OINT-2 trial, which met its primary endpoint of statistically significant and clinically meaningful reductions in under eye bags?
Added By: pjloriaCan you discuss the mechanism of action for XAF5, and compare it to current treatment options? How do they compare in terms of safety and efficacy?
Added By: pjloriaGiven the current information, what are the chances of approval for XAF5?
Added By: pjloriaWhat are important things to look for in the Phase IIb/III trial, which is expected to conclude at the end of 2016?
Added By: pjloriaAssuming it gets approved, what percentage of existing patients do you think will use XAF5? What percentage of new patients do you think will use XAF5?
Added By: pjloriaIf XAF5 gets approved, will this motivate any patients who were not previously seeking treatment to try the new option?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
